Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesProjected economic impact of clinical findings of generic entry of topiramate on G4 European countries
Current Medical Research and Opinion, 06/19/09
Paradis PE et al. - Higher health costs were projected for G4 European countries from the Canadian experience following the generic entry of topiramate.
Pierre Emmanuel Paradis, 06/19/09
| We forecasted the overall budget impact of generic entry of topiramate on G4 European countries using real-life data on patients with epilepsy in Canada. Our projections indicate that system-wide health costs generated by users of topiramate would rise from 3.5% to 24.4% in all four countries one year after generic entry. Therefore, the savings from lower generic drug costs (-6% to -14%) are expected to be more than compensated by the combination of higher non-topiramate health care costs following generic substitution (14% to 18%), and of market-size variations (-4% to +14%). Health care payers in each country, i.e. government, insurers, and individuals, would assume comparable shares of this additional cost burden. |
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Costs and benefits of dropout schedules of test-restudy practice: Implications for student learning
Applied Cognitive Psychology, 12/07/09
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
PLoS Medicine, 12/04/09
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Sponsor
Article Search
Sponsor